Ertapenem, the first of a new group of carbapenemsSHAH, Pramod M; ISAACS, Robin D.Journal of antimicrobial chemotherapy (Print). 2003, Vol 52, Num 4, pp 538-542, issn 0305-7453, 5 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Effects of Omeprazole on Plasma Levels of RaltegravirIWAMOTO, Arian; WENNING, Larissa A; AZROLAN, Neal et al.Clinical infectious diseases. 2009, Vol 48, Num 4, pp 489-492, issn 1058-4838, 4 p.Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 InfectionMARKOWITZ, Martin; NGUYEN, Bach-Yen; CAMPBELL, Havilland et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 3, pp 350-356, issn 1525-4135, 7 p.Article

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus : a phase II randomised controlled trial. CommentaryCAHN, Pedro; SUED, Omar; HARVEY, Charlotte M et al.Lancet (British edition). 2007, Vol 369, Num 9569, issn 0140-6736, 1235-1236,1261-1269 [11 p.]Article